Benefits
Raises hemoglobin in pregnancy as well as other iron salts
In a randomized trial of 120 pregnant women with low hemoglobin, 200 mg of iron a day as ferrous fumarate, ferrous sulfate, ferrous ascorbate or carbonyl iron worked equally well for hemoglobin and other blood measures, and all four were judged equally cost-effective. Side effects were most common on ferrous fumarate (56.7 percent).
Higher elemental iron content
Ferrous fumarate is 33 percent elemental iron by weight, compared with 20 percent for ferrous sulfate and 12 percent for ferrous gluconate, so less of the salt is needed for the same amount of iron. Supplement Facts panels list the elemental iron, so that is the number to compare.
Digestive tolerability compared with other iron salts
Ferrous fumarate is not reliably gentler than ferrous sulfate. In 404 pregnant women, 20 to 60 mg of iron a day as fumarate caused no dose-related rise in digestive complaints, but 80 mg brought more constipation. Comparing two trials, ferrous bisglycinate at 25 mg caused fewer complaints than fumarate at 40 mg or sulfate at 50 mg.
Less fatigue when iron stores are low
The placebo-controlled fatigue trials used ferrous sulfate, which supplies the same ferrous iron as fumarate. In 198 fatigued, non-anemic women with ferritin below 50 ug/L, 80 mg/day of elemental iron cut fatigue scores 47.7% vs 28.8% on placebo over 12 weeks. In 176 iron-deficient blood donors, fatigue improved on oral ferrous fumarate and IV iron alike, but with no placebo arm. This applies only to low iron confirmed by a blood test.
Mechanism of action
Ferrous (Fe²⁺) Form
Like ferrous sulfate and gluconate, ferrous fumarate supplies iron in the ferrous (Fe²⁺) form, which is absorbed through the DMT1 transporter without first being reduced.
Fumaric Acid Carrier
Fumaric acid, the carrier, is a normal intermediate of the citric acid cycle that cells use to make energy.
Standard Iron Absorption and Function
Once absorbed, iron is built into hemoglobin, myoglobin, cytochromes and iron-sulfur enzymes, the same as iron from any source. In iron-depleted women, taking galacto-oligosaccharide fiber with ferrous fumarate raised the share of iron absorbed.
Clinical trials
Prospective, randomized, open-label, blinded-endpoint trial comparing ferrous sulfate, ferrous fumarate, ferrous ascorbate and carbonyl iron at 200 mg of elemental iron a day. (Gamad et al. 2021, Journal of Obstetrics and Gynaecology Research)
120 pregnant women with iron-deficiency anemia, 30 per group.
All four salts were equally effective at raising hemoglobin and other blood measures, and equally cost-effective. Adverse effects were most common in the ferrous fumarate group (56.7 percent).
Two randomized, double-blind studies: ferrous fumarate at 20, 40, 60 or 80 mg iron a day, and ferrous bisglycinate 25 mg or ferrous sulphate 50 mg a day, from weeks 15 to 19 of pregnancy to delivery. (Milman et al. 2024, Journal of Pregnancy)
482 healthy women with an uncomplicated single pregnancy (404 in the fumarate dose study, 78 in the bisglycinate and sulphate study).
Between 20 and 60 mg of iron a day as fumarate, digestive complaints did not rise with dose; 80 mg brought significantly more constipation and laxative use. Across the two studies, bisglycinate 25 mg caused fewer complaints than fumarate 40 mg or sulphate 50 mg, which were similar. No woman needed to stop or change her iron.
Pre-planned secondary analysis of the IronWoMan randomized trial: one 1 g infusion of ferric carboxymaltose or 100 capsules of ferrous fumarate (100 mg iron with 20 mg vitamin C each) over 8 to 12 weeks. (Macher et al. 2020, Nutrients)
176 iron-deficient whole-blood and platelet donors in Austria (138 women, 38 men) aged 18 to 65 with ferritin 30 ng/mL or below.
Fatigue, restless legs and sleep quality improved after treatment (p < 0.001), as did headaches, breathlessness, dizziness and palpitations, with no difference between oral and intravenous iron. There was no placebo group. The study was supported by Vifor Pharma and G.L. Pharma, maker of the oral capsules.
Multicentre randomized trial (POPEYE) of one intravenous dose of ferric carboxymaltose against 12 weeks of oral ferrous fumarate. (Bevers et al. 2023, Journal of Pediatrics)
64 children aged 8 to 18 with inflammatory bowel disease and anemia at 11 centres.
At 1 month, 6-minute walking distance improved more with the infusion (z-score +0.71 vs -0.11), but there was no difference at 3 or 6 months. Hemoglobin rose at the same rate in both groups.